HIV Infections Clinical Trial
Official title:
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Verified date | June 2019 |
Source | Gilead Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment.
Status | Completed |
Enrollment | 252 |
Est. completion date | July 18, 2018 |
Est. primary completion date | July 31, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Key Inclusion Criteria: Cohort 1 (treatment-experienced switch) - Must not have a history of known resistance to elvitegravir (EVG), tenofovir disoproxil fumarate (TDF), or emtricitabine (FTC) - Plasma HIV-1 RNA concentrations (at least two measurements) at undetectable levels (according to the local assay being used) in the 6 months preceding the screening visit and have HIV-1 RNA < 50 copies/mL at screening - Estimated glomerular filtration rate (GFR) 30-69 mL/min according to the Cockcroft-Gault formula for creatinine clearance, using actual weight - May be currently enrolled in Gilead studies GS-US-236-0102, GS-US-236-0103, and GS-US-216-0114, but will be eligible to enroll only after the Week 144 visit for that study is complete; or currently receiving Stribild® (STB) or atazanavir (ATV)/cobicistat (COBI) + Truvada (TVD) in Gilead studies GS-US-236-0104 or GS-US-216-0105, but will be eligible to enroll only after the Week 48 visit for that study is complete. Cohort 2 (treatment-naive) - Plasma HIV-1 RNA levels = 1,000 copies/mL at screening - Screening genotype report provided by Gilead Sciences must show sensitivity to EVG, FTC, and TDF - No prior use of any approved or investigational antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PrEP), or post-exposure prophylaxis (PEP), up to 6 months prior to screening - Estimated GFR 30-69 mL/min according to the Cockcroft Gault formula for creatinine clearance, using actual weight All Cohorts: All individuals must meet all of the following inclusion criteria to be eligible for participation in this study: - The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures - CD4+ count of = 50 cells/µL - Stable renal function: serum creatinine measurements to be taken at least once (within three months of screening) - Cause of underlying chronic kidney disease (eg hypertension, diabetes) stable, without change in medical management, for 3 months prior to baseline - Normal electrocardiogram (ECG) - Hepatic transaminases (AST and ALT) = 5 x upper limit of normal (ULN) - Total bilirubin = 1.5 mg/dL, or normal direct bilirubin - Adequate hematologic function - Serum amylase = 5 x ULN - Females of childbearing potential must agree to utilize highly effective contraception methods (two separate forms of contraception, one of which must be an effective barrier method, or be non-heterosexually active, practice sexual abstinence) from screening throughout the duration of study treatment and for 30 days following the last dose of study drug - Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing - Males must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 30 days following discontinuation of investigational medicinal product. A highly effective method of contraception is defined as two separate forms of contraception, one of which must be an effective barrier method, or males must be non-heterosexually active, or practice sexual abstinence Key Exclusion Criteria: - A new AIDS-defining condition (excluding CD4 cell count and percentage criteria) diagnosed within the 30 days prior to screening,with the exception of the first two bullet points - Hepatitis C virus (HCV) antibody positive. Individuals who are HCV positive, but have a documented negative HCV RNA, are eligible - Hepatitis B surface antigen (HBVsAg) positive - Individuals receiving drug treatment for Hepatitis C, or individuals who are anticipated to receive treatment for Hepatitis C during the course of the study - Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, etc.) - Females who are breastfeeding - Positive serum pregnancy test - Have an implanted defibrillator or pacemaker - Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance - A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma - Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline - Individuals on hemodialysis, other forms of renal replacement therapy, or on treatment for underlying kidney diseases (including prednisolone and dexamethasone) - Individuals receiving ongoing therapy with any medications not to be used with EVG, COBI, FTC, or TAF or individuals with any known allergies to the excipients of E/C/F/TAF Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Australia | Holdsworth House Medical Practice | Darlinghurst | New South Wales |
Australia | Clinical Research Infectious Diseases Department- Alfred Hospital | Melbourne | Victoria |
Australia | Prahran Market Clinic | Prahran | Victoria |
Dominican Republic | Instituto Dominicano de Estudios Virologicos (IDEV) | Santo Domingo | |
France | Hopital de la Croix Rousse | Lyon | |
France | GHPS Service des maladies infectieuses et tropicales pavillon Laveran unité de recherche clinique | Paris | |
Mexico | Hospital Civil de Guadalajara Dr. Juan I. Menchaca | Guadalajara | Jalisco |
Netherlands | University Medical Center Utrecht | Utrecht | |
Spain | Germans Trias i Pujol University Hospital | Barcelona | |
Spain | Hospital Universitari de Bellvitge | Barcelona | |
Spain | Hospital La Paz | Madrid | |
Thailand | Department of Preventive and Social Medicine, Faculty of Medicine, Siriraj Hospital | Bangkok | |
Thailand | Faculty of Medicine Ramathibodi Hospital, Mahidol University | Bangkok | |
Thailand | HIV-NAT, Thai Red Cross AIDS Research Centre | Bangkok | |
Thailand | Srinagarind Hospital, Khon Kaen University | Khon Kaen | |
United Kingdom | Brighton & Sussex University Hospitals NHS Trust | Brighton | |
United Kingdom | Chelsea and Westminster NHS Foundation Trust Hospital | London | |
United Kingdom | Kings College London | London | |
United Kingdom | Central Manchester University Hospitals NHS foundation Trust | Manchester | |
United States | Albany Medical College | Albany | New York |
United States | Upstate Infectious Diseases Associates | Albany | New York |
United States | University of Colorado | Aurora | Colorado |
United States | St. Hope Foundation | Bellaire | Texas |
United States | Be Well Medical Center, P.C. | Berkley | Michigan |
United States | Pacific Oaks Medical Group | Beverly Hills | California |
United States | Community Research Initiative of New England | Boston | Massachusetts |
United States | Jacobi Medical Center | Bronx | New York |
United States | Montefiore Medical Center | Bronx | New York |
United States | University of Cincinnati | Cincinnati | Ohio |
United States | MetroHealth Medical Center | Cleveland | Ohio |
United States | North Texas Infectious Diseases Consultants, PA | Dallas | Texas |
United States | Infectious Disease Specialists of Atlanta | Decatur | Georgia |
United States | National Jewish Health | Denver | Colorado |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Gary J. Richmond, MD PA | Fort Lauderdale | Florida |
United States | Midway Immunology and Research Center | Fort Pierce | Florida |
United States | Garcias' Family Health Group | Harlingen | Texas |
United States | Kaiser Permanente | Hayward | California |
United States | Gordon E. Crofoot MD, PA | Houston | Texas |
United States | Therapeutic Concepts, PA | Houston | Texas |
United States | Indiana University School of Medicine | Indianapolis | Indiana |
United States | The Kansas City Care Clinic (KC Free Health Clinic) | Kansas City | Missouri |
United States | Health for Life Clinic PLLC | Little Rock | Arkansas |
United States | Long Beach Education and Research Consultants | Long Beach | California |
United States | Anthony Mills MD, Inc | Los Angeles | California |
United States | LA Gay & Lesbian Center - Jeffrey Goodman Special Care Clinic | Los Angeles | California |
United States | Peter J Ruane, MD, Inc | Los Angeles | California |
United States | Mercer University | Macon | Georgia |
United States | North Shore University Hospital/Division of Infectious Diseases | Manhasset | New York |
United States | Hennepin County Medical Center | Minneapolis | Minnesota |
United States | Jersey Shore University Medical Center | Neptune | New Jersey |
United States | Saint Michael's Medical Center | Newark | New Jersey |
United States | Idocf/Valuhealthmd | Orlando | Florida |
United States | Desert Medical Group Inc. dba Desert Oasis Healthcare Medical Group | Palm Springs | California |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | University of PA HIV Clinical Trials Unit | Philadelphia | Pennsylvania |
United States | Maricopa Integrated Health System - McDowell Clinic | Phoenix | Arizona |
United States | Pueblo Family Physicians | Phoenix | Arizona |
United States | Aids Care | Rochester | New York |
United States | Kaiser Permanente Medical Group | Sacramento | California |
United States | Southampton Healthcare, Inc. | Saint Louis | Missouri |
United States | Kaiser Permanente CTU San Francisco | San Francisco | California |
United States | Metropolis Medical | San Francisco | California |
United States | Southwest CARE Center | Santa Fe | New Mexico |
United States | Peter Shalit, MD | Seattle | Washington |
United States | The Research Institute | Springfield | Massachusetts |
United States | University of South Florida | Tampa | Florida |
United States | Dupont Circle Physician's Group | Washington | District of Columbia |
United States | Triple O Research Institute, P.A. | West Palm Beach | Florida |
United States | Rowan Tree Medical, P.A. | Wilton Manors | Florida |
Lead Sponsor | Collaborator |
---|---|
Gilead Sciences |
United States, Australia, Dominican Republic, France, Mexico, Netherlands, Spain, Thailand, United Kingdom,
Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96 — View Citation
Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team. Switchin — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24 | eGFR is a measurement of the kidney's ability to filter blood. | Baseline; Week 24 | |
Primary | Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24 | eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex. | Baseline; Week 24 | |
Primary | Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24 | eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex. | Baseline; Week 24 | |
Secondary | Change From Baseline in Actual GFR (aGFR) of E/C/F/TAF for Participants Enrolled in the PK/PD Substudy | aGFR was directly measured using iohexol plasma clearance (CLiohexol). | Baseline; Week 2, 4, or 8; Week 24 | |
Secondary | Percent Change From Baseline in C-type Collagen Sequence (CTX) at Weeks 24 and 48 | CTX is a biomarker of bone turnover. | Baseline; Weeks 24 and 48 | |
Secondary | Percent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 24 and 48 | P1NP is a biomarker of bone turnover. | Baseline; Weeks 24 and 48 | |
Secondary | Percent Change From Baseline in Retinol Binding Protein (RBP) to Creatinine Ratio (µg/g) at Weeks 24, 48, 96, and 144 | Urine RBP is a renal biomarker which is used to evaluate drug-induced kidney injury. | Baseline; Weeks 24, 48, 96, and 144 | |
Secondary | Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio (µg/g) at Weeks 24, 48, 96, and 144 | Urine beta-2-microglobulin is a renal biomarker which is used to evaluate drug-induced kidney injury. | Baseline; Weeks 24, 48, 96, and 144 | |
Secondary | Percentage of Participants Experiencing Adverse Events or Graded Laboratory Abnormalities | Adverse events (AEs) and graded laboratory abnormalities occurring during the E/C/F/TAF treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event. | Baseline up to Week 240 plus 30 days | |
Secondary | Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144 | The percentage of participants achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. | Weeks 24, 48, 96, and 144 | |
Secondary | Pharmacokinetic (PK) Parameter: Cmax of TAF | Cmax is defined as the maximum concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | PK Parameter: Tmax of TAF | Tmax is defined as the time of Cmax. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | PK Parameter: Clast of TAF | Clast is defined as the last observable concentration of drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | PK Parameter: Tlast of TAF | Tlast is defined as the time of Clast. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | PK Parameter: ?z of TAF | ?z is defined as the terminal elimination rate constant. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | PK Parameter: AUCtau of TAF | AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | PK Parameter: t1/2 of TAF | t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study | TFV-DP is an active phosphorylated metabolite of tenofovir alafenamide. AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). Blood draws for this outcome may have been at the Week 2, 4, or 8 visit. | Predose, and 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose | |
Secondary | Change From Baseline in the eGFR_CG at Weeks 48, 96, and 144 | eGFR is a measurement of the kidney's ability to filter blood. | Baseline; Weeks 48, 96, and 144 | |
Secondary | Change From Baseline in eGFR_CKD-EPI,cysC at Weeks 48, 96, and 144 | eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,cysC method is adjusted for age and sex. | Baseline; Weeks 48, 96, and 144 | |
Secondary | Change From Baseline in eGFR_CKD-EPI,Creatinine at Weeks 48, 96, and 144 | eGFR is a measurement of the kidney's ability to filter blood. The eGFR_CKD-EPI,creatinine method is adjusted for age, race, and sex. | Baseline; Weeks 48, 96, and 144 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |